Gene:
HTR2A
5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs17288723 18477A>G, 28437693T>C, 361+8832A>G, 47457693T>C, 613+8832A>G
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs1928040 28427236G>A, 28934C>T, 361+19289C>T, 47447236G>A, 613+19289C>T
G > A
Intronic
No VIP available CA VA
rs6305 264C>T, 28446622G>A, 47466622G>A, 516C>T, 9548C>T, Asp172=, Asp88=
G > A
Synonymous
Asp88Asp
No VIP available CA VA
rs6311 -1438, -510G>A, -998G>A, 28451478C>T, 4692G>A, 47471478C>T, G>A, HTR2A c.-1438G>A, HTR2A:, HTR2A: -1438G/A, HTR2A:-1438G>A
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs6312 -344G>A, 145G>A, 28450824C>T, 47470824C>T, 5346G>A, Asp49Asn
C > T
Missense
Asp49Asn
No VIP available CA VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
No VIP available CA VA
rs6314 1102C>T, 1354C>T, 28389034G>A, 47409034G>A, 67136C>T, HTR2A: C1354T, HTR2A: His452Tyr, His368Tyr, His452Tyr
G > A
Missense
His368Tyr
No VIP available No Clinical Annotations available VA
rs659734 28415283G>A, 362-25509C>T, 40887C>T, 47435283G>A, 614-25509C>T
G > A
Intronic
No VIP available CA VA
rs7997012 28391985A>G, 362-2211T>C, 47411985A>G, 5-HTR2A intron 2 variant, 614-2211T>C, 64185T>C
A > G
Intronic
No VIP available CA VA
rs9316233 28413355C>G, 362-23581G>C, 42815G>C, 47433355C>G, 614-23581G>C
C > G
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  5-HT2A
PharmGKB Accession Id: PA193

Details

Cytogenetic Location: chr13 : q14.2 - q14.2
GP mRNA Boundary: chr13 : 47407513 - 47471169
GP Gene Boundary: chr13 : 47404513 - 47481169
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics
    Genes involved in serotonin synthesis, release, reuptake, and in mediation of the antidepressant effect of selective serotonin reuptake inhibitors (SSRI) in human brain.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

No related genes are available

Curated Information ?

Curated Information ?

Publications related to HTR2A: 72

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. European journal of clinical pharmacology. 2014. Cargnin Sarah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014. Zai Gwyneth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Family-Based Clinical Associations and Functional Characterization of the Serotonin 2A Receptor Gene (HTR2A) in Autism Spectrum Disorder. Autism research : official journal of the International Society for Autism Research. 2014. Smith Ryan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. British journal of clinical pharmacology. 2014. Reynolds Gavin P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT2A receptor. The pharmacogenomics journal. 2014. Cooper J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and genomics. 2013. Hall-Flavin Daniel K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics. 2013. Sánchez Martín Almudena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics. 2013. López-Rodríguez Rosario, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics in major depression: a comprehensive meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2013. Niitsu Tomihisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast cancer research and treatment. 2013. Henry N Lynn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013. Severino Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2013. Lenze Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of clinical response to risperidone. Pharmacogenomics. 2013. Llerena Adrián, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology. 2013. Arias Bárbara, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multiple Regulatory Variants Modulate Expression of 5-Hydroxytryptamine 2A Receptors in Human Cortex. Biological psychiatry. 2012. Smith Ryan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. The pharmacogenomics journal. 2012. Lohoff F W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics. 2012. Narasimhan Sneha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder. The pharmacogenomics journal. 2011. Lohoff F W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neuroscience letters. 2011. Viikki Merja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Receptor targets for antidepressant therapy in bipolar disorder: An overview. Journal of affective disorders. 2011. Fountoulakis Konstantinos N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. The American journal of psychiatry. 2011. Greenwood Tiffany A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International journal of clinical pharmacy. 2011. Wilffert Bob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. The pharmacogenomics journal. 2010. Liu W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. The pharmacogenomics journal. 2010. Correia C T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HTR2A is associated with SSRI response in Major Depressive Disorder in a Japanese cohort. Neuromolecular medicine. 2010. Kishi Taro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressive treatment. European archives of psychiatry and clinical neuroscience. 2010. Zobel Astrid, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. International clinical psychopharmacology. 2010. Noro Magali, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Horstmann Sonja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2010. Laje Gonzalo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. Journal of clinical psychopharmacology. 2010. Murata Yusuke, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. The pharmacogenomics journal. 2010. Laika B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy. 2009. Thomas Kelan L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neuroscience research. 2009. Kishi Taro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. Journal of Alzheimer's disease : JAD. 2009. Angelucci Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009. Perroud Nader, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport. 2009. Illi Ari, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenetics and genomics. 2009. Peters Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry research. 2009. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic predictors of response to antidepressants in the GENDEP project. The pharmacogenomics journal. 2009. Uher Rudolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant response: an update. Human genomics. 2009. Drago Antonio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. The pharmacogenomics journal. 2009. Wilkie M J V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin 5-HT2A receptor gene variants influence antidepressant response to repeated total sleep deprivation in bipolar depression. Progress in neuro-psychopharmacology & biological psychiatry. 2008. Benedetti Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry research. 2008. Thomas Pramod, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Movement disorders associated with aripiprazole use: a case series. The International journal of neuroscience. 2009. Hall Deborah A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety. Pharmacogenomics. 2008. Kronenberg Sefi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. The Journal of clinical psychiatry. 2008. Ujike Hiroshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2008. Tanaka Misuzu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA and cell biology. 2007. Boke Omer, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve. 2007. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. The American journal of psychiatry. 2007. Paddock Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Bishop Jeffrey R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American journal of human genetics. 2006. McMahon Francis J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Risperidone-related weight gain: genetic and nongenetic predictors. Journal of clinical psychopharmacology. 2006. Lane Hsien-Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Suzuki Yutaro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics and antidepressant drugs. Annals of medicine. 2006. Binder Elisabeth B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006. Kato Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. Pharmacogenetics and genomics. 2005. Huang Shuwen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. The pharmacogenomics journal. 2006. Davies M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. The pharmacogenomics journal. 2006. Hong C-J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of antidepressant medication intolerance. The American journal of psychiatry. 2003. Murphy Greer M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacology bulletin. 2003. Ellingrod Vicki L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The pharmacogenomics journal. 2003. Yamanouchi Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. The American journal of psychiatry. 2002. Lane Hsien-Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. American journal of medical genetics. 2002. Veenstra-VanderWeele Jeremy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neuroscience letters. 2001. Minov C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. Journal of psychiatric research. 2000. Serretti A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. Journal of psychiatry & neuroscience : JPN. 1999. Joober R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981. Brogden R N, et al. PubMed

LinkOuts

UniProtKB:
5HT2A_HUMAN (P28223)
Ensembl:
ENSG00000102468
GenAtlas:
HTR2A
GeneCard:
HTR2A
MutDB:
HTR2A
ALFRED:
LO000287R
HuGE:
HTR2A
Comparative Toxicogenomics Database:
3356
ModBase:
P28223
HumanCyc Gene:
HS02392
IUPHAR Receptor:
5-HT2A (6)
HGNC:
5293

Common Searches